NICE set to recommend chronic constipation treatment
pharmafile | August 4, 2010 | News story | Sales and Marketing | Movetis, NICE, Resolor
NICE has provisionally recommended Belgium-based Movetis’s Resolor as an option for the treatment of chronic constipation in women where laxatives have failed to provide relief.
The draft guidance will come as a boost for the gastroenterology specialist that launched Resolor across Europe in October last year and was made commercially available in Germany for the first quarter of 2010.
Professor Peter Littlejohns, clinical and public health director at NICE, said: “Prucalopride has been preliminarily recommended as a clinically and cost-effective treatment for women with chronic constipation who have failed to achieve adequate relief from at least two prior laxative treatments.
“There have not been any new laxative treatments available in the UK for over 25 years and current treatment for this distressing condition is very limited, and has some very unpleasant side-effects. We are pleased therefore, that the evidence considered by the Appraisal Committee shows this drug would be a useful treatment for people who have been unable to manage their constipation with standard laxatives.”
Resolor (prucalopride) is indicated for women who have tried at least two different types of laxative and lifestyle changes for at least six months, but have not had relief from constipation.
Current treatments are limited for people in whom laxatives fail to provide adequate relief from constipation, and may include intrusive interventions that only give a short-term benefit.
Chronic constipation that cannot be remedied by two different courses of laxatives affects two to three times as many women as men, with prevalence rates of around 10% in women under 65 years of age in the UK. Rates are often higher – around 20% – in women over 65 years of age.
The appraisal consultation document is available for comment until Tuesday 24 August 2010 with final guidance expected for publication this December.
Later in 2010, Movetis expects to introduce Resolor in the Netherlands and to continue the preparations for the product launch in France, Belgium and Luxemburg.
Movetis is currently working with US healthcare giant Johnson & Johnson to prepare for the filing and eventual launch of Resolor outside of Europe.
Ben Adams
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
